论文部分内容阅读
目的:对卡托普利、舒血宁在高原性心脏病心力衰竭中的应用价值进行评价。方法:研究取60例高原性心脏病心力衰竭患者,患者于2013年1月份-2016年1月份入院治疗。随机性分组,对照组采用常规方法进行治疗,共30例;实验组同时采用卡托普利、舒血宁进行治疗,共30例。观察患者的治疗情况,并进行分析和比较。结果:在总有效率方面,实验组的总有效率为93.3%(28/30),对照组的总有效率为73.3%(22/30),组间数据差异性明显,P<0.05;在血气分析、全血黏度、红细胞压积方面,患者的PaCO_2、全血黏度、红细胞压积下降,PaO_2上升,实验组的升幅、降幅比对照组大,组间数据差异性明显,P<0.05。结论:采用卡托普利、舒血宁对高原性心脏病心力衰竭进行治疗,能够有效改善患者的血气分析以及血液情况,值得推荐。
Objective: To evaluate the value of captopril and shuxuening in the treatment of heart failure due to high altitude heart disease. Methods: Sixty patients with heart failure due to heart disease were enrolled. Patients were admitted to hospital from January 2013 to January 2016. Random group, the control group using conventional methods for treatment, a total of 30 cases; experimental group with captopril, Shuxuening for treatment, a total of 30 cases. Observe the patient’s treatment, and analyze and compare. Results: The total effective rate was 93.3% (28/30) in the experimental group and 73.3% (22/30) in the control group. There was significant difference between the two groups (P <0.05) Blood gas analysis, whole blood viscosity, hematocrit, patients PaCO_2, whole blood viscosity, hematocrit decreased, PaO_2 increased, the increase and decrease of the experimental group than the control group, significant difference between groups data, P <0.05. Conclusion: The use of captopril and shuxuening in the treatment of heart failure due to high altitude heart disease can effectively improve blood gas analysis and blood conditions in patients, which is worth recommending.